JP2021514400A5 - - Google Patents

Info

Publication number
JP2021514400A5
JP2021514400A5 JP2020566548A JP2020566548A JP2021514400A5 JP 2021514400 A5 JP2021514400 A5 JP 2021514400A5 JP 2020566548 A JP2020566548 A JP 2020566548A JP 2020566548 A JP2020566548 A JP 2020566548A JP 2021514400 A5 JP2021514400 A5 JP 2021514400A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered
heteroaryl
heteroatoms selected
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514400A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/018773 external-priority patent/WO2019164948A1/en
Publication of JP2021514400A publication Critical patent/JP2021514400A/ja
Publication of JP2021514400A5 publication Critical patent/JP2021514400A5/ja
Pending legal-status Critical Current

Links

JP2020566548A 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法 Pending JP2021514400A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632819P 2018-02-20 2018-02-20
US62/632,819 2018-02-20
US201862744086P 2018-10-10 2018-10-10
US62/744,086 2018-10-10
PCT/US2019/018773 WO2019164948A1 (en) 2018-02-20 2019-02-20 Inhibitors of egfr and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2021514400A JP2021514400A (ja) 2021-06-10
JP2021514400A5 true JP2021514400A5 (cg-RX-API-DMAC7.html) 2022-02-25

Family

ID=67687390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566548A Pending JP2021514400A (ja) 2018-02-20 2019-02-20 Egfrの阻害剤およびその使用法

Country Status (6)

Country Link
US (1) US20200390783A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755690A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021514400A (cg-RX-API-DMAC7.html)
AU (1) AU2019225806A1 (cg-RX-API-DMAC7.html)
CA (1) CA3087288A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019164948A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087716A1 (en) 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
CN119317636A (zh) * 2023-03-07 2025-01-14 艾博生物科技(上海)有限公司 编码活化EGFR突变肽的免疫调节治疗性mRNA组合物
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254159A1 (en) * 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
WO2006061126A2 (en) * 2004-12-09 2006-06-15 F. Hoffmann-La Roche Ag Dibenzoxazepinone derivatives
US20070105835A1 (en) * 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
WO2009124399A1 (en) * 2008-04-11 2009-10-15 Thallion Pharmaceuticals Inc. Inhibition of cell migration by a farnesylated dibenzodiazepinone
RU2016116516A (ru) * 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
EP2379559B1 (en) * 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2017248186B2 (en) * 2016-04-07 2021-10-21 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
AU2017254702B2 (en) * 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
CA3087716A1 (en) * 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof

Similar Documents

Publication Publication Date Title
PE20240879A1 (es) Inhibidor sos1 y uso del mismo
CY1122949T1 (el) ΠΥΡΑΖΟΛΟ[1,5-a]ΠΥΡΑΖΙΝ-4-ΥΛΟ ΠΑΡΑΓΩΓΑ ΩΣ JAK-ΑΝΑΣΤΟΛΕΙΣ
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
JP2018522879A5 (cg-RX-API-DMAC7.html)
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2021514011A5 (cg-RX-API-DMAC7.html)
JP2020510091A5 (cg-RX-API-DMAC7.html)
CY1125142T1 (el) Παραγωγα 2-φαινυλ-3,4-διυδροπυρρολο[2,1- f][1,2,4]τριαζινονης ως αναστολεις φωσφοδιεστερασης και χρησεις αυτων
JP2016540742A5 (cg-RX-API-DMAC7.html)
JP2009536620A5 (cg-RX-API-DMAC7.html)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
EA201290260A1 (ru) Бензимидазол-имидазольные производные
JP2016518437A5 (cg-RX-API-DMAC7.html)
RU2017105781A (ru) Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение
JP2018538248A5 (cg-RX-API-DMAC7.html)
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2023520330A5 (cg-RX-API-DMAC7.html)
JP2014521688A5 (cg-RX-API-DMAC7.html)
JP2010504346A5 (cg-RX-API-DMAC7.html)
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
JP2022525069A5 (cg-RX-API-DMAC7.html)
RU2016137356A (ru) Соединение нафтиламида, способ его получения и применение
JP2016531868A5 (cg-RX-API-DMAC7.html)